加拿大血液与呼吸道标本中3型肺炎链球菌分离株的表型与分子特征:CANWARD 2007-21
CANWARD监测显示,2007-2021年3039株肺炎链球菌中8.7%(n=264)为3型,其中64.0%来自呼吸道、36.0%来自血液。226株测序分离株中81.4%为ST180(GPSC12),ST8561比例从7.2%升至16.6%。与2007-11年相比,2017-21年3型分离株表型耐药(P=0.0007)和遗传耐药决定因子(P=0.004)比例均增加。
要点
- 3型占3039株肺炎链球菌的8.7%,64.0%来自呼吸道、36.0%来自血液。
- 测序的226株中81.4%为ST180(GPSC12),ST8561比例从7.2%升至16.6%。
- 2017-21年较2007-11年,3型表型耐药(P=0.0007)与遗传耐药决定因子(P=0.004)比例增加。
核心结论
- 来自GPSC12的3型肺炎链球菌在加拿大持续占主导,ST8561比例增加。
- 3型分离株中表型耐药和携带遗传耐药决定因子的比例随时间增加,反映全球GPSC12基因型中已知耐药决定因子的增加。
研究设计与样本
- CANWARD监测项目对2007年至2021年所有肺炎链球菌分离株进行抗菌药物敏感性试验和血清分型。
- 从264株3型分离株中选取226/264(85.6%)进行全基因组测序,以确定序列型(ST)/克隆群(CC)及耐药决定因子(erm、mefAE、tetM、cat、folA、folP)与耐药表型的对应关系。
主要发现
- 2007年至2021年共获得3039株肺炎链球菌,其中8.7%(n=264)为3型,64.0%来自呼吸道、36.0%来自血液。
- 226株测序的3型分离株中,184株(81.4%)为ST180(GPSC12)。
- 研究期间ST8561(ST180的单 locus 变异株)比例从7.2%升至16.6%。
- 比较2017-21年与2007-11年,3型分离株表型耐药比例增加(P=0.0007),遗传耐药决定因子比例增加(P=0.004),主要由于近期扩展的携带cat、tetM和mef决定因子的ST180分支。
关键数值与推荐
- 3型分离株占3039株肺炎链球菌的8.7%(n=264)。
- 226株测序分离株中ST180(GPSC12)占81.4%(184株)。
- ST8561比例从7.2%升至16.6%。
- 表型耐药比例增加P=0.0007,遗传耐药决定因子比例增加P=0.004(2017-21年 vs 2007-11年)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. METHODS: As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype. RESULTS: Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017-21 to 2007-11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants. CONCLUSIONS: S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.
引用
- Schellenberg JJ, Adam HJ, Baxter MR, et al. Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007-21. J Antimicrob Chemother. 2024. PMID: 39092981. doi:10.1093/jac/dkae272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。